Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases

• Published in: Rheumatology (Oxford, England) Vol. 63; no. 2; pp. 298 - 308
• Main Authors: Taylor, Peter C, Choy, Ernest, Baraliakos, Xenofon, Szekanecz, Zoltan, Xavier, Ricardo M, Isaacs, John D, Strengholt, Sander, Parmentier, Julie M, Lippe, Ralph, Tanaka, Yoshiya
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 01.02.2024
• Subjects: Antirheumatic Agents - therapeutic use; Arthritis, Rheumatoid - drug therapy; Humans; Janus Kinase Inhibitors - pharmacology; Janus Kinase Inhibitors - therapeutic use; Janus Kinases - metabolism; Psoriasis - drug therapy; upadacitinib; filgotinib; abrocitinib; mode of action; peficitinib; baricitinib; tofacitinib

Janus kinases (JAKs) are a family of cytosolic tyrosine kinases that regulate cytokine signal transduction, including cytokines involved in a range of inflammatory diseases, such as RA, psoriasis, atopic dermatitis and IBD. Several small-molecule JAK inhibitors (JAKis) are now approved for the treat...